Loading…

Grant Application Form

Complete all steps to submit your application

Pre-filled from selected grant
REFINE-Lung (formerly known as CONVOLUTE): A randomised open-label phase III trial of REduced Frequency pembrolizumab ImmuNothErapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design.

National Institute for Health and Care Research · United Kingdom · £312.8M GBP

Back to Grant
Grant Information

Provide details about the grant you are applying for

$
Applicant Information

Tell us about yourself and your organization

$
Proposal & Supporting Documents

Provide additional details and upload your proposal document

Accepted formats: PDF, DOC, DOCX. Max size: 10MB